Patents Examined by Douglas M Willis
-
Patent number: 11965122Abstract: Calcium reacting photoproteins are a class of self-illuminating proteins that emit light upon contact with calcium. Fluorescent Proteins are small proteins that change the color of light when excited. Fluorescent Proteins and Calcium Activated Photoproteins can be used to enhance, dazzle, amaze, startle, and otherwise entertain an audience by their direct application on to the audience, surroundings, the actors, or sprayed on settings as in the newer 4D movies. The disclosure comprises novel Coelenterazine compounds and methods of use, including a simple delivery device for the photoprotein to create unique and novel cinematic, theatrical, stage, movie and musical concert optical effects by their luminous reaction upon contact with surfaces that contain calcium. Calcium is ubiquitous in and on most surfaces and in the environment; it is this unique property of calcium that makes this a novel use of the photoproteins for entertainment. A generic formula of Coelenterazine as shown.Type: GrantFiled: June 10, 2021Date of Patent: April 23, 2024Assignee: PROLUME, LTD.Inventors: Bruce Bryan, Hendrik Schmidt, Millard Cull
-
Patent number: 11964976Abstract: Novel pyrido[3?,4?:4,5]pyrrolo[3,2-c][1,6]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3?,4?:4,5]pyrrolo[3,2-c][1,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: September 12, 2023Date of Patent: April 23, 2024Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 11964981Abstract: Pyrimido[4,5-b]indole compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrimido[4,5-b]indole compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: September 18, 2023Date of Patent: April 23, 2024Assignee: KING FAISAL UNIVERSITYInventors: Michelyne Haroun, Christophe Tratrat
-
Patent number: 11958842Abstract: A combination product comprising a carbapenem and a compound of formula (I?), or a pharmaceutically acceptable salt thereof: a pharmaceutical composition comprising the combination product; and methods of treating bacterial or fungal infections using the combination product and pharmaceutical composition.Type: GrantFiled: April 26, 2021Date of Patent: April 16, 2024Assignee: ADJUTEC PHARMA ASInventors: Pål Rongved, Ove Alexander Høgmoen Åstrand, Elvar Ørn Viktorsson, Ørjan Samuelson, Adam Heikal, Ole Andreas Løchen Økstad, Geir Kildahl-Andersen
-
Patent number: 11958856Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: Pharmaceutical compositions containing said compounds, and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.Type: GrantFiled: July 21, 2022Date of Patent: April 16, 2024Assignee: Janssen Pharmaceutica NVInventors: Guozhang Xu, Zhijie Liu
-
Patent number: 11952376Abstract: The invention relates to compounds of formula (I): or a salt thereof, wherein R1, G, L1, L2, L3, and Y are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are inhibitors of one, or both of, ?v?1 integrin and ?v?6 integrin that are useful for treating fibrosis such as in nonalcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).Type: GrantFiled: October 18, 2021Date of Patent: April 9, 2024Assignee: PLIANT THERAPEUTICS, INC.Inventors: Jacob Cha, Manuel Muñoz, Maureen Reilly, Nicole Cooper, Katerina Leftheris, David J. Morgans, Jr., Timothy Hom, Yajun Zheng, Christopher Bailey, Darren Finkelstein
-
Patent number: 11952366Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: It further discloses a pharmaceutical composition comprising the compounds of Formula (I) and their uses, in particular in the treatment of diseases or disorders associated to increased relative to physiological or desired RhoJ/Cdc42 levels of expression or function.Type: GrantFiled: November 23, 2021Date of Patent: April 9, 2024Assignees: Fondazione Istituto Italiano Di TecnologiaInventors: Marco De Vivo, Anand Ganesan, Jose Antonio Ortega Martinez, Sohail Jahid
-
Patent number: 11945819Abstract: Novel dimethyl 7-bromo-1-(4-substituted benzoyl)pyrrolo[1,2-?]quinoline-2,3-dicarboxylates compounds, having the structure: A method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The dimethyl 7-bromo-1-(4-substituted benzoyl)pyrrolo[1,2-?]quinoline-2,3-dicarboxylates compounds, identified as anti-inflammatory agents, are useful for treating inflammation, pain, and swelling in a patient.Type: GrantFiled: September 21, 2023Date of Patent: April 2, 2024Assignee: KING FAISAL UNIVERSITYInventors: Katharigatta N. Venugopala, Pran Kishore Deb, Pramod Patil, Osama I. Alwassil, Mohamed A. Morsy, Bandar Aldhubiab, Vijaykumar Uppar, Mahmoud Kandeel, Praveen B. Managutti, Basavaraj Padmashali
-
Patent number: 11945823Abstract: Pyrrolo[2,3-d]pyrimidine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[2,3-d]pyrimidine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: September 14, 2023Date of Patent: April 2, 2024Assignee: KING FAISAL UNIVERSITYInventors: Michelyne Haroun, Christophe Tratrat
-
Patent number: 11945787Abstract: Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising the same, and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis are described. The compounds include imidazoles of Formula VI: wherein G1 is pyrrolidine, pyrazolidine, imidazolidine piperidine, or piperazine and G2 is alkyl, cycloalkyl, heterocycle, or aryl. The pyrrolidine, pyrazolidine, imidazolidine, piperidine, or piperazine of G1 and the alkyl, cycloalkyl, heterocycle, or aryl of G2 are optionally substituted with one or more substituents independently selected from the group consisting of halogen, NO2, CN, C1-C6 alkyl, C1-C6 haloalkyl, NH2, OH, OC1-C6 alkyl, C(O)H, C(O)C1-C6 alkyl, C(O)NH2, C(O)OH, and C(O)OC1-C6 alkyl. Variations applications for the described compounds, and combination therapies are further described as well.Type: GrantFiled: March 15, 2021Date of Patent: April 2, 2024Assignee: Ela Pharma LTDInventors: Ilana Nathan, Boris Khalfin
-
Patent number: 11939335Abstract: Provided herein are inhibitors of PARG, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the PARG inhibitory compounds for the treatment of disease.Type: GrantFiled: May 19, 2023Date of Patent: March 26, 2024Assignee: 858 THERAPEUTICS, INC.Inventors: James M. Veal, Jeffrey A. Stafford, Donald S. Karanewsky, Shyama Herath
-
Patent number: 11939334Abstract: The present disclosure relates to a novel PLK1 degradation inducing compound having a structure according to Formula I, a method for preparing the same, and the use thereof. The compounds of the present disclosure exhibit an effect of inducing PLK1 degradation. Therefore, the compounds of the present disclosure may be effectively utilized for preventing or treating PLK1-related diseases.Type: GrantFiled: August 10, 2022Date of Patent: March 26, 2024Assignee: UPPTHERA, INC.Inventors: Soo Hee Ryu, Im Suk Min, Han Kyu Lee, Seong Hoon Kim, Hye Guk Ryu, Keum Young Kang, Sang Youn Kim, So Hyun Chung, Jun Kyu Lee, Gibbeum Lee
-
Patent number: 11932642Abstract: Novel pyrido[3?,4?:4,5]pyrrolo[3,2-b][1,6]naphthyridine compounds of the formula as shown below, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3?,4?:4,5]pyrrolo[3,2-b][1,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.Type: GrantFiled: August 21, 2023Date of Patent: March 19, 2024Assignee: KING FAISAL UNIVERSITYInventors: Christophe Tratrat, Michelyne Haroun
-
Patent number: 11919905Abstract: Disclosed are a pyridyl imidazobenzodiazepine propionate (compound 1) and the synthesis and use thereof. Also provided are intermediates for the preparation. Compound 1 provided by the present invention has an obvious venous anesthesia activity equivalent to that of the positive control drug remimazolam p-toluenesulfonate or remimazolam besylate. In addition, compound 1 can be significantly reduced in mouse model experiments, and same can even overcome common limb jitters, head tilting, opisthotonus and other side effects caused by the remimazolam besylate or remimazolam p-toluenesulfonate as a drug during development in preclinical animal experiments, thereby allowing same to be used in the preparation of intravenous anesthetics. The structural general formula of compound 1 is as follows, wherein each group and substituent are as defined in the description.Type: GrantFiled: December 28, 2018Date of Patent: March 5, 2024Assignee: Hangzhou Adamerck Pharmlabs, Inc.Inventor: Youmao Qi
-
Patent number: 11918553Abstract: The present specification discloses one or more anti-oncogenic phytochemicals comprising one or more compounds of chemical formula I: wherein R1is independently selected from H, CH3 or C2H5or is not present; R2 is independently selected from H, CH3 or C2H5 or is not present; provided that when R1 is not present, R2 is selected from H, CH3 or C2H5 and when R2 is not present R1 is selected from H, CH3 or C2H5: R3 is a C4-40 straight or branched chain, alkyl or alkylene and optionally substituted with one or more groups independently selected from CH3, OH, SH, NH2, OMe, OEt, N(H)Me and NMe2; and X is independently selected from CH3, OH, SH, NH2, OMe, OEt, N(H)Me, and NMe2, as well as, extracts, pharmaceutical compositions and medicaments comprising the one or more anti-oncogenic phytochemicals disclosed herein, methods of preparing such extracts, pharmaceutical compositions, and medicaments comprising the one or more anti-oncogenic phytochemicals , and methods and uses for treating a neoplasm or a cancer usiType: GrantFiled: June 16, 2023Date of Patent: March 5, 2024Assignee: Ostentus Therapeutics, Inc.Inventors: Guido Marcucci, Antonio G. Cagnolo, Richard T. Nguyen, William Graff
-
Patent number: 11919908Abstract: The present application provides deazaguaine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.Type: GrantFiled: December 20, 2021Date of Patent: March 5, 2024Assignee: Incyte CorporationInventors: Andrew W. Buesking, Onur Atasoylu, Cheng-Tsung Lai, Padmaja Polam, Liangxing Wu, Wenqing Yao
-
Patent number: 11911354Abstract: The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (II): wherein R1, R2, R3, X and Y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. More particularly, the present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of Formula (I): wherein R2, R3, and X, are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt.Type: GrantFiled: December 15, 2021Date of Patent: February 27, 2024Assignee: BASFInventors: Hilde Steineger, David Alan Fraser, Tore Skjæret
-
Patent number: 11912719Abstract: The present invention relates to indoline-based compounds that inhibit Rho-associated protein kinase (ROCK) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.Type: GrantFiled: December 29, 2021Date of Patent: February 27, 2024Assignee: Cervello Therapeutics, LLC.Inventors: Matthew Randolph Lee, Anthony Joseph Varano, Jr., Thomas P. Bobinski
-
Patent number: 11911466Abstract: The present invention provides a compound of the formula (1): wherein X, R1, R2, R3, R4, R5, R6, Y1, Y2, L, and m are as defined in the description, and a pharmaceutically acceptable salt thereof, which are useful as a vaccine adjuvant.Type: GrantFiled: January 25, 2022Date of Patent: February 27, 2024Assignee: Sumitomo Pharma Co., Ltd.Inventors: Hidenori Kimura, Hitoshi Ban, Yoshiaki Isobe, Hitoshi Watanabe
-
Patent number: 11912702Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).Type: GrantFiled: December 22, 2021Date of Patent: February 27, 2024Assignee: Alkermes, Inc.Inventors: Nathan Oliver Fuller, John A. Lowe, III